DNA Damage, Granulosa Cells
Conditions
Keywords
Ovarian Reserve, Flow Cytometry, Sperm Injections, Intracytoplasmic
Brief summary
Deoxyribonucleic acid (DNA) damage of granulosa cells obtained during oocyte retrieval will be evaluated by flow cytometry with detection of Histone H2A.X and Phosphorylated Gamma H2A.X protein levels in patients with low ovarian reserve and unexplained infertile patients as a control group undergoing intracytoplasmic sperm injection (ICSI) treatment. Fertilization, embryo quality, transfer rate, implantation, clinical pregnancy will be recorded as well as demographic data. DNA damage of granulosa cells will be compared between two groups. The effect of DNA damage of granulosa cells on fertilization, quality of oocyte and embryo, implantation, and clinical pregnancy will be also evaluated.
Detailed description
Granulosa cells surrounding the oocytes will be mechanically obtained during the oocyte pick-up procedure in women undergoing intracytoplasmic sperm injection (ICSI) treatment due to unexplained infertility and low ovarian reserve. Deoxyribonucleic acid (DNA) damage in these cells will be evaluated by flow cytometry. Fertilization rates, embryo quality by grading, and transfer rates will also be assessed. Implantation and clinical pregnancy rates will be recorded as well as demographic data such as age, body-mass index, smoking, alcohol use, employment, coexisting chronic disease, infertility duration, etiology of infertility, treatment protocol. Implantation will be evaluated by determination of serum human chorionic gonadotropin (hCG) at day 15 following an embryo transfer. Clinical pregnancy will be diagnosed upon presence of gestational sac on ultrasound examination. DNA damage of granulosa cells will be compared between low ovarian reserve group and control group. The effect of DNA damage of granulosa cells on fertilization, quality of oocyte and embryo, implantation, and clinical pregnancy will be also evaluated.
Interventions
None listed
Sponsors
Zeynep Kamil Maternity and Pediatric Research and Training Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* For patients who are undergoing in Vitro Fertilization (IVF) treatment with Low ovarian reserve, Antimullerian Hormone level must be lower than 1 ng/mL * For patients who are undergoing in Vitro Fertilization (IVF) treatment with Unexplained infetility, Antimullerian Hormone level must be greater than 1,5 ng/mL
Exclusion criteria
* Chronic systemic disease (rheumatoid arthritis, hypertension, diabetes..) * Endocrinopathy (Thyroid, prolactin... abnormalities) * Chemotherapy or radiotherapy history * Endometriosis * Policystic ovary syndrome * Male infetility
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determining the correlation of ovarian reserve and age factor with DNA Damage markers in granulosa cells. | 1 day | Demographic data will be noted for each patient at the day of oocyte retrieval, and DNA damage markers will be shown by flowcytometry at the same day. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fertilization defined as the presence of two pronuclei under light microscope one day after intracytoplasmic sperm injection procedure | 1 day after ICSI procedure | Presence of two pronuclei under light microscope |
| Implantation defined as positive serum human chorionic gonadotropin levels 12 days after embryo transfer | 12 days after embryo transfer | Positive human chorionic gonadotropin levels |
| Clinical pregnancy will be defined as the presence of gestational sac in transvaginal ultrasonographic examination 5 weeks after embryo transfer | 5 weeks | Presence of a gestational sac in transvaginal ultrasonographic examination |
Contacts
Primary ContactErman Ciftci, MD
Outcome results
None listed